fda semaglutide mash Approves Wegovy® for Treatment FDA Approves Semaglutide for MASH

Already a BodySite subscriber

[3] The evidence supports Ozempic as an effective option for addressing the metabolic dysfunction underlying insulin resistance, though it should be noted that individual responses vary

Bliddal H, et al

The clinical principle is start low and go slow. Your dose should escalate based on how you are tolerating it, not on a manufacturers pre-set schedule

Sustainable Progress: By addressing dietary, physical, and emotional factors, individuals are more likely to achieve and maintain long-term success

The broader literature on subcutaneous injection pharmacokinetics shows that absorption rate differences between sites are a function of tissue blood flow and fat composition